CLOs on the Move

Gliknik

www.gliknik.com

 
Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.gliknik.com
  • 801 W Baltimore St
    Baltimore, MD USA 21201
  • Phone: 410.685.0662

Executives

Name Title Contact Details

Similar Companies

CINDE Journal

CINDE Journal is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

BioAgilytix

BioAgilytix is a leading bioanalytical contract research organization (CRO) that supports the development of novel therapeutic biologics and biosimilars. Located in Research Triangle Park, North Carolina, BioAgilytix specializes in large-molecule bioanalysis providing critical insight into the safety, efficacy, and mechanism of action of drug candidates throughout the clinical trial process. Specifically, BioAgilytix offers assay development, validation, and sample analysis services for immunoassays and cell-based assays under non-GLP, spirit-of-GLP, and GLP, as well as product release testing under GMP. BioAgilytix is an engaged and energetic partner committed to delivering exceptional value and veteran expertise through a collaborative process that consistently results in successful projects.

Pharmgate

Pharmgate Animal Health is headquartered in Wilmington, North Carolina, and provides innovative and high-quality products that help the livestock industry optimize animal health, efficiency and production. Pharmgate Animal Health is celebrating its 10th Anniversary in 2018. The company`s pharmaceutical production facilities are located in Omaha, Nebraska with vaccine research and manufacturing operations based in St. Paul, Minnesota.

Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers.

Outlook Therapeutics

Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.